Project Portfolio
Axenoll Life Sciences AG is a Swiss medical technology company based in Zurich, Switzerland. The company was founded in 2014 and has a 100%-owned subsidiary in Jena, Axenoll 3D Printing GmbH, which serves as the operational unit.
The 3D screen printing technology allows large identical quantities to be produced with a virtually free choice of materials and the combination of materials in different layers. Axenoll’s portfolio includes a wide range of 3D products such as wound dressings, screening chips and scaffolds for complex cell models.
Axenoll’s printing technology also enables innovative, cost‑efficient solutions for cosmetic applications such as facial masks, microneedles, and scar reduction.
saniva diagnostics GmbH is a German medical technology company based in Erfurt, founded in January 2019, focusing on diagnostics.
saniva diagnostics GmbH is developing NeuroMex, a scalable screening instrument for the early detection of neurodegenerative diseases such as Alzheimer’s disease. NeuroMex addresses the need for a low‑threshold, non‑invasive method to identify patients at very early stages of disease.
The clinical study programs involving healthy volunteers as well as patients in prodromal stages were successfully completed and confirm the system’s suitability for detecting mild cognitive impairment. The focus is now on preparing for market launch and scaling the screening approach in the preventive care setting.
The novaxomx GmbH is a joint venture between Curasan AG and Xlife Sciences AG. The aim is to research and develop exosomes for use in musculoskeletal diseases. novaxomx has signed a license agreement with Lysatpharma for the use of exosomes. novaxomx develops exosomes for applications in regenerative medicine, such as bone regeneration.
In initial cell culture experiments, the positive effect of exosomes on bone cells has been demonstrated. The data were published in a high‑impact journal. In the next step, the effects on bone regeneration are to be reproduced in an animal bone model.
x-kidney diagnostics GmbH was incorporated in 2019 and is based in Erfurt, Germany. The company is dedicated to the development of new methods for the early identification of kidney diseases.
The early diagnosis of kidney diseases is essential for their successful treatment and management. However, the early dioganosis is hampered by the lack of biomarkers for early stages. Currently, clinically validated biomarkerare recognized when the kidney is already damaged by 50%. Diabetic nephropathy is the most common cause of dialysis in Europe and the United States.
x-kidney diagnostics GmbH focuses on the identification of novel biomarkers by a proteomic based research approach in the Alport syndrome, a glomerulonephropathy with well defined animal models. Based on the comparable histopathogenesis of different glomerulonephropathies, Alport syndrome was used as surrogate model.In animals (mice and dogs) with Alport syndrome over 100 differentially expressed proteins could be identified before the onset of the disease. The most promising biomarker will be validated in a dataset of approximately 200 clinically well described Alport syndrome patients with serum, plasma and urine samples. After the successful validation of the biomarkers in humans, the next step is the development of diagnostic test for the early detection of kidney disease.
In cooperation with the licensing partner Quant Biomarkers, the biomarkers are being validated and prepared for commercialization. To this end, Quant Biomarkers successfully secured Innosuisse funding of about CHF 1 Million.
x-nuclear diagnostic GmbH is a spin-off of University Hospital (Universitätsklinikum) Jena founded in 2019 and based in Erfurt, Germany.
x-nuclear diagnostics GmbH researches on technologies in the field of diagnostic for application in nuclear medicine. In nuclear medical diagnostics, patients are administered radioactive drugs which accumulate in various concentrations in human organs or tissues (depending on their pharmacological properties). Due to their radioactivity, their temporal and spatial distribution in the body can be detected externally and made visible through suitable measuring instruments.
The company’s liver-specific radiotracer DAZAmed® is manufactured and marketed in GMP compliance by inflamed pharma GmbH under a licensing agreement. The tracer has already been used in more than 70 patients, and its benefits have been demonstrated in various publications.
The PET tracer has high potential for clinical application because it is less toxic than other radiodiagnostics and can also be used for metal-heavy implants (unlike existing tracers which cannot be used for metal implants). In the DACH region alone there are over 300 nuclear medicine specialists who could also use the PET tracer. If the centers in the US and Asia are included, sales potential is expected to exceedEUR 1 billion per year
